These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 36581082)

  • 21. Comparison of insulin detemir and insulin glargine in a basal-bolus regimen, with insulin aspart as the mealtime insulin, in patients with type 1 diabetes: a 52-week, multinational, randomized, open-label, parallel-group, treat-to-target noninferiority trial.
    Heller S; Koenen C; Bode B
    Clin Ther; 2009 Oct; 31(10):2086-97. PubMed ID: 19922879
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of glargine in pregnant women with type 1 diabetes mellitus: a case-control study.
    Imbergamo MP; Amato MC; Sciortino G; Gambina M; Accidenti M; Criscimanna A; Giordano C; Galluzzo A
    Clin Ther; 2008 Aug; 30(8):1476-84. PubMed ID: 18803989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Basal insulin requirements on continuous subcutaneous insulin infusion during the first 12 months after diagnosis of type 1 diabetes mellitus.
    Ramchandani N; Ellis MK; Jain S; Bhandari S; Anhalt H; Maclaren NK; Ten S
    J Diabetes Sci Technol; 2010 May; 4(3):610-4. PubMed ID: 20513327
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Marked improvements in glycaemic outcomes following insulin pump therapy initiation in people with type 1 diabetes: a nationwide observational study in Scotland.
    Jeyam A; Gibb FW; McKnight JA; Kennon B; O'Reilly JE; Caparrotta TM; Höhn A; McGurnaghan SJ; Blackbourn LAK; Hatam S; McCrimmon RJ; Leese G; Lindsay RS; Petrie J; Chalmers J; Philip S; Wild SH; Sattar N; McKeigue PM; Colhoun HM;
    Diabetologia; 2021 Jun; 64(6):1320-1331. PubMed ID: 33686483
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Efficacy of Two Different Methods to Initiate Sensor-Augmented Insulin Pumps: A Randomized Controlled Trial.
    Moreno-Fernandez J; Gómez FJ; Gálvez Moreno MÁ; Castaño JP
    J Diabetes Res; 2016; 2016():4171789. PubMed ID: 28004007
    [No Abstract]   [Full Text] [Related]  

  • 26. Factors associated with adherence to continuous subcutaneous insulin infusion in pediatric diabetes.
    Babar GS; Ali O; Parton EA; Hoffmann RG; Alemzadeh R
    Diabetes Technol Ther; 2009 Mar; 11(3):131-7. PubMed ID: 19216689
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predicting the effectiveness of insulin pump therapy on glycemic control in clinical practice: a retrospective study of patients with type 1 diabetes from 10 outpatient diabetes clinics in Sweden over 5 years.
    Clements M; Matuleviciene V; Attvall S; Ekelund M; Pivodic A; Dahlqvist S; Fahlén M; Haraldsson B; Lind M
    Diabetes Technol Ther; 2015 Jan; 17(1):21-8. PubMed ID: 25470010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term metabolic effects of continuous subcutaneous insulin infusion therapy in type 1 diabetes.
    Cohen ND; Hong ES; Van Drie C; Balkau B; Shaw J
    Diabetes Technol Ther; 2013 Jul; 15(7):544-9. PubMed ID: 23617252
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glycemic control and selected pregnancy outcomes in type 1 diabetes women on continuous subcutaneous insulin infusion and multiple daily injections: the significance of pregnancy planning.
    Cyganek K; Hebda-Szydlo A; Katra B; Skupien J; Klupa T; Janas I; Kaim I; Sieradzki J; Reron A; Malecki MT
    Diabetes Technol Ther; 2010 Jan; 12(1):41-7. PubMed ID: 20082584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Continuous Subcutaneous Insulin Infusion in Neonates and Infants Below 1 Year: Analysis of Initial Bolus and Basal Rate Based on the Experiences from the German Working Group for Pediatric Pump Treatment.
    Kapellen TM; Heidtmann B; Lilienthal E; Rami-Merhar B; Engler-Schmidt C; Holl RW
    Diabetes Technol Ther; 2015 Dec; 17(12):872-9. PubMed ID: 26509360
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Basal and Bolus Insulin Dose Changes after Switching Basal Insulin to Insulin Degludec in Patients with Type 1 Diabetes Mellitus: A Pilot Study.
    Hamamoto Y; Honjo S; Fujimoto K; Tokumoto S; Ikeda H; Wada Y; Koshiyama H
    Clin Drug Investig; 2017 Sep; 37(9):845-852. PubMed ID: 28624930
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes.
    Hanaire-Broutin H; Melki V; Bessières-Lacombe S; Tauber JP
    Diabetes Care; 2000 Sep; 23(9):1232-5. PubMed ID: 10977011
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Glycemic control and its associated factors in children and adolescents with type 1 diabetes mellitus].
    Ling P; Zhang Y; Luo SH; Zheng XY; Qiu LL; Yang DZ; Ai HY; Lü J; Yuan FY; Zhang XW; Xu W; Liang H; Yan JH; Yao B; Weng JP
    Zhonghua Yi Xue Za Zhi; 2018 Dec; 98(46):3762-3766. PubMed ID: 30541218
    [No Abstract]   [Full Text] [Related]  

  • 34. Glucose variability as the risk factor of preeclampsia in pregnant patients with type 1 diabetes mellitus.
    Tiselko AV; Kapustin RV; Milyutina YP; Borovik NV; Abashova EI; Yarmolinskaya MI
    J Matern Fetal Neonatal Med; 2022 Dec; 35(25):9639-9646. PubMed ID: 35264056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuous subcutaneous insulin infusion vs modern multiple injection regimens in type 1 diabetes: an updated meta-analysis of randomized clinical trials.
    Pala L; Dicembrini I; Mannucci E
    Acta Diabetol; 2019 Sep; 56(9):973-980. PubMed ID: 30945047
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Assessment of the effectiveness of long-term insulin pump therapy using a combined goal of HbA
    Quirós C; Viñals C; Giménez M; Roca D; Conget I
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Nov; 66(9):534-539. PubMed ID: 31133475
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reducing glucose variability with continuous subcutaneous insulin infusion is associated with reversal of axonal dysfunction in type 1 diabetes mellitus.
    Kamel J; Loh M; Cook M; MacIsaac RJ; Roberts LJ
    Muscle Nerve; 2020 Jan; 61(1):44-51. PubMed ID: 31613996
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of a glucose meter connected to a mobile app on glycemic control and adherence to self-care tasks in patients with T1DM and LADA: a parallel-group, open-label, clinical treatment trial.
    de Oliveira FM; Calliari LEP; Feder CKR; de Almeida MFO; Pereira MV; de Almeida Fagundes Alves MTT; Garcia SAD; Reis LDD; Salles JEN
    Arch Endocrinol Metab; 2021 Nov; 65(2):185-197. PubMed ID: 33905630
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis.
    Yeh HC; Brown TT; Maruthur N; Ranasinghe P; Berger Z; Suh YD; Wilson LM; Haberl EB; Brick J; Bass EB; Golden SH
    Ann Intern Med; 2012 Sep; 157(5):336-47. PubMed ID: 22777524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Memory of insulin pumps and their record as a source of information about insulin therapy in children and adolescents with type 1 diabetes.
    Pańkowska E; Skórka A; Szypowska A; Lipka M
    Diabetes Technol Ther; 2005 Apr; 7(2):308-14. PubMed ID: 15857233
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.